Inovio Pharmaceuticals (INO) EBITDA (2010 - 2026)

Inovio Pharmaceuticals has disclosed EBITDA across 17 years of filings, most recently posting -$18.6 million for Q2 2026.

• In Q2 2026, EBITDA rose 19.32% year-over-year to -$18.6 million; the TTM figure through Jun 2026 stood at -$79.3 million (up 17.31% YoY), while the FY2025 annual figure was -$86.8 million, up 22.76% from the prior year.
• EBITDA came in at -$18.6 million for Q2 2026 at Inovio Pharmaceuticals, up from -$21.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$17.5 million in Q4 2025 to a low of -$104.1 million in Q2 2022.
• Average EBITDA over 5 years is -$36.2 million, with a median of -$29.4 million recorded in 2023.
• Year-over-year, EBITDA plunged 36.49% in 2022 and jumped 64.43% in 2023.
• Over 5 years, EBITDA stood at -$55.9 million in 2022, then soared by 51.04% to -$27.4 million in 2023, then advanced by 25.64% to -$20.4 million in 2024, then gained by 14.2% to -$17.5 million in 2025, then declined by 6.57% to -$18.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$18.6 million in Q2 2026, -$21.9 million in Q1 2026, and -$17.5 million in Q4 2025.